Metformin And Dichloroacetate Combination Exert A Synergistic Effect On Cell Viability Of Oral Squamous Cell Carcinoma

• Published in: ENT Updates Vol. 9; no. 2; pp. 68 - 73
• Main Authors: Seniz INANC, KELES, Didem, ESKİİZMİR, Gorkem, BASBİNAR, Yasemin, OKTAY, Gulgun
• Format: Journal Article
• Language: English; Turkish
• Published: Istanbul Continuous Education and Scientific Research Association (CESRA) 01.08.2019; AVES
• Subjects: Antidiabetics; Clinical outcomes; Drug therapy; Oral cancer; Squamous cell carcinoma
• ISSN: 2149-7109; 2149-6498
• DOI: 10.32448/entupdates.569464

Objective: To assess the effects of Metformin, Dichloroacetate (DCA) and their combination on cell viability in oral squamous cell carcinoma, UPCI-SCC-131 cell line. Methods: UPCI-SCC-131 cells were plated in 96 E-plate (1x104 cells/well) and were treated with Metformin (1-16mM) and/or DCA (15-120mM) for 24-48-72h. xCELLigence SP system was used to monitor real time cell viability. In addition, drug combination index was analyzed with CompuSyn software according to Chou-Talalay method. Results: Half-maximal inhibitory concentrations (IC50) of Metformin and DCA were found to be 3mM and 23mM, respectively, for 72 hours. CI values (0.76-0.80) in all combination groups below 1 indicated that Metformin/DCA combination had a moderate synergistic effect on cell viability in UPCI-SCC-131 cells. Discussion: Metformin/DCA combination synergistically decreased the cell viability of UPCI-SCC-131 cells. Therefore, a combined application of Metformin and DCA may be considered as a candidate therapy for the “drug repositioning” of the treatment of oral cavity cancer.